TWEAKR產(chǎn)品信息
英文名稱：Tumor necrosis factor receptor superfamily member 12A
中文名稱：腫瘤壞死因子受體超家族成員12A
靶點(diǎn)別稱：TNFRSF12A,FGF-inducible 14,FN14,TweakR,CD266
物種：Human
屬性：Protein
標(biāo)記：Unconjugated
內(nèi)毒素（Endotoxin）
Less than 1.0 EU per μg by the LAL method.
純度（Purity）
>95% as determined by SDS-PAGE.
制劑（Formulation）
Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 100 mM Glycine, pH7.5 with trehalose as protectant.
Contact us for customized product form or formulation.
重構(gòu)方法（Reconstitution）
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲(chǔ)（Storage）
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
TWEAKR分子背景
Tumor necrosis factor receptor superfamily member 12A (TNFRSF12A) is also known as Fibroblast growth factor-inducible immediate-early response protein 14 (FN14 or FGF-inducible 14), Tweak-receptor, CD antigen CD266. TNFRSF12A contains one TNFR-Cys repeat. TNFRSF12A is highly expressed in heart, placenta and kidney. TNFRSF12A is receptor for TNFSF12/TWEAK, and is weak inducer of apoptosis in some cell types. TNFRSF12A / FN14 promotes angiogenesis and the proliferation of endothelial cells.
關(guān)鍵字： TWEAKR;TWEAKR蛋白;TNFRSF12A蛋白;ACRO;百普賽斯;
百普賽斯集團(tuán)ACROBiosystems Group（股票代碼：301080）是成立于2010年的跨國生物科技公司，是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺(tái)型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團(tuán)業(yè)務(wù)遍布全球，橫跨亞洲、北美洲、歐洲，在中國、美國、瑞士等12個(gè)城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計(jì)服務(wù)客戶超6000家，與全球Top 20醫(yī)藥企業(yè)均建立了長期、穩(wěn)定的合作伙伴關(guān)系。集團(tuán)旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學(xué)等。